Keyphrases
Clinical Outcomes
100%
Graft-versus-host Disease (GvHD)
100%
Safety Profile
100%
Placebo-controlled Study
100%
Siplizumab
100%
Natural Killer Cells
14%
Placebo Groups
14%
Placebo
14%
Acceptable Safety
14%
Adverse Events
14%
T Cells
14%
Monoclonal Antibody
14%
Bone Marrow
14%
Infection Rate
14%
Stem Cells
14%
Allograft
14%
Humanized
14%
Multiple Dose
14%
Tolerability
14%
Hematologic
14%
Major Complications
14%
Both Bones
14%
Disease Treatment
14%
Clinical Development
14%
Methylprednisolone
14%
Meaningful Difference
14%
Corticosteroid Therapy
14%
Laboratory Results
14%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
100%
Placebo-Controlled Study
100%
Siplizumab
100%
Graft Versus Host Reaction
42%
Placebo
28%
CD2 Antigen
28%
Combination Therapy
14%
Receptor
14%
Adverse Event
14%
Monoclonal Antibody
14%
Tolerability
14%
Methylprednisolone
14%
Secondary Infection
14%
Diseases
14%
Immunology and Microbiology
Acute Graft Versus Host Disease
100%
Siplizumab
100%
Graft-Versus-Host Disease
42%
CD2
28%
Natural Killer Cell
14%
T Cell
14%
Stem Cell
14%
Monoclonal Antibody
14%
Methylprednisolone
14%
Laboratory Test
14%
Multiple Drug Dose
14%
Allograft
14%